MagnetisMM-15

Elranatamab Post Trial Access: An Open-Label, Single-Arm Study For Participants with Multiple Myeloma Continuing From Pfizer-Sponsored Elranatamab Clinical Studies

What will happen during the trial?

This is a single-arm elranatamab post-trial access study. Participants will receive elranatamab. All participants will receive elranatamab until disease progression, unacceptable toxicity, withdrawal of consent, study termination or, elranatamab becomes commercially accessible in the participant's country.

More Information

Trial Status
Not yet accepting
Trial Phase
Phase 4
Enrollment
72 patients (estimated)
Sponsors
Pfizer
Tags
Bispecific Antibody, B-Cell Maturation Antigen (BCMA), CD3
Trial Type
Treatment
Last Update
3 months ago
SparkCures ID
1793
NCT Identifier
NCT06057402

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.